Don’t miss out on the next big thing in the life sciences.

Maher Masoud, President & CEO, MaxCyte®

In this Q&A, Masoud reflects on what drew him to lead MaxCyte®, how its Flow Electroporation® platform and SeQure™ gene editing characterization services are enabling the next generation of cell therapies, and why the company positions itself not as a vendor but as an embedded partner in its customers’ success. He also addresses the challenges of a tightened biotech funding environment, the culture he is building at MaxCyte®, and what it means to him personally when the work comes full circle — as it did when a former sickle cell patient, treated with a therapy enabled by MaxCyte® technology, later joined the company to help advance that same mission.